Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Innate Pharma SA
F:IDDA
Innate Pharma SA
F:IDDA
Price:
1.14
EUR
0.88%
Market Closed
Market Cap:
€92.3m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Innate Pharma SA
F:IDDA
|
FR |
|
F
|
Frasers Property (Thailand) PCL
SET:FPT
|
TH |
Wall St Price Targets
IDDA Price Forecast
Based on 4 analysts
Based on 4 analysts
+394% Upside
from
€1.14
today
Innate Pharma SA (IDDA)’s 12-month stock price forecast through October 2027 has a consensus target of €5.63, implying 394% upside. The forecast is based on price targets from 4 Wall Street analysts.
IDDA Analyst Rating
No ratings yet
No ratings yet
Innate Pharma SA Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IDDA's stock price target?
Price Target
5.63
EUR
5.63
EUR
According to Wall Street analysts, the average 1-year price target for IDDA is 5.63 EUR with a low forecast of 4.95 EUR and a high forecast of 7.35 EUR.
What is the Revenue forecast for Innate Pharma SA?
Projected CAGR
92%
92%
Over the last 13 years, the compound annual growth rate for Revenue has been -10%. The projected CAGR for the next 7 years is 92%.
What is the Gross Profit forecast for Innate Pharma SA?
Projected CAGR
994%
994%
Over the last 13 years, the compound annual growth rate for Gross Profit has been -22%. The projected CAGR for the next 3 years is 994%.